Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.

Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, O'Neill G, Metters K, Gottesdiener KG, Wagner JA.

Clin Pharmacol Ther. 2008 Jun;83(6):840-7. Epub 2007 Sep 19.

PMID:
17882161
2.

The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.

Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28.

PMID:
21526889
3.

Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.

Liu F, Vessey L, Wenning L, Connolly S, Buckland M, Johnson-Levonas AO, Denker A, Wagner JA, Lai E.

J Clin Pharmacol. 2010 Jul;50(7):823-8. doi: 10.1177/0091270009356571. Epub 2010 Mar 2.

PMID:
20197486
4.

Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.

Stroh M, Wenning L, Luo WL, Desai R, Bi S, Keshavarz S, Lazarus N, Lunde NM, Smith WB, Schwartz M, Stone J, Wagner J, Lai E, Dishy V.

Am J Ther. 2009 Sep-Oct;16(5):379-84. doi: 10.1097/MJT.0b013e318197c59d.

PMID:
19433974
5.

Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects.

Lauring B, Dishy V, Luo WL, Laterza O, Patterson J, Cote J, Chao A, Larson P, Gutierrez M, Wagner JA, Lai E.

J Clin Pharmacol. 2009 Dec;49(12):1426-35. doi: 10.1177/0091270009339593. Epub 2009 Oct 15.

PMID:
19833861
6.

Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.

Dishy V, Liu F, Ebel DL, Atiee GJ, Royalty J, Reilley S, Paolini JF, Wagner JA, Lai E.

J Clin Pharmacol. 2009 Apr;49(4):416-22. doi: 10.1177/0091270009332246. Epub 2009 Feb 26.

PMID:
19246721
7.

Single therapeutic and supratherapeutic doses of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, do not prolong the QTcF interval in healthy volunteers.

Luo WL, Crumley T, Ebel D, Atiee GJ, Royalty J, Johnson-Levonas AO, Wagner J, Lai E.

J Clin Pharmacol. 2010 Nov;50(11):1273-9. doi: 10.1177/0091270009360042. Epub 2010 Jan 27.

PMID:
20107202
8.

Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.

Wang YH, Liu F, Luk JA, Nirula A, Johnson-Levonas AO, Lasseter KC, Marbury TC, Lunde NM, Wagner JA, Lai E.

J Clin Pharmacol. 2011 Mar;51(3):406-12. doi: 10.1177/0091270010369240. Epub 2010 May 19.

PMID:
20484612
9.

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.

Am J Ther. 2009 May-Jun;16(3):215-23. doi: 10.1097/MJT.0b013e31818f9c68.

PMID:
19454860
10.

Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

Wang YH, Schwartz JI, Luo WL, Jumes P, Desai R, Wenning LA, Wagner JA, Lai E.

Cardiovasc Ther. 2011 Apr;29(2):140-5. doi: 10.1111/j.1755-5922.2009.00129.x.

PMID:
20337634
11.

The effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers.

Van Hecken A, Depré M, De Lepeleire I, Thach C, Oeyen M, Van Effen J, Laethem T, Mazina K, Crumley T, Wenning L, Gottesdiener KM, Deutsch P, Clement P, Lai E, de Hoon JN.

Eur J Clin Pharmacol. 2007 Feb;63(2):135-41. Epub 2007 Jan 3.

PMID:
17200838
12.

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.

Cardiovasc Ther. 2009 Winter;27(4):239-45. doi: 10.1111/j.1755-5922.2009.00104.x.

PMID:
19903187
13.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.

Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF.

J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. doi: 10.1016/j.jaci.2009.07.006. Epub 2009 Sep 12.

PMID:
19748656
14.

Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.

Schwartz JI, Liu F, Wang YH, Pramanik B, Johnson-Levonas AO, Gutierrez MJ, Lai E, Wagner JA.

Am J Ther. 2009 Nov-Dec;16(6):487-95. doi: 10.1097/MJT.0b013e3181985130.

PMID:
19940609
15.

Non-obligatory role of prostaglandin D2 receptor subtype 1 in rosacea: laropiprant in comparison to a placebo did not alleviate the symptoms of erythematoelangiectaic rosacea.

Krishna R, Guo Y, Schulz V, Cord-Cruz E, Smith S, Hair S, Nahm WK, Draelos ZD.

J Clin Pharmacol. 2015 Feb;55(2):137-43. doi: 10.1002/jcph.383. Epub 2014 Sep 4.

PMID:
25142778
16.

Pharmacodynamics, pharmacokinetics, and safety of AM211: a novel and potent antagonist of the prostaglandin D2 receptor type 2.

Bain G, King CD, Brittain J, Hartung JP, Dearmond I, Stearns B, Truong YP, Hutchinson JH, Evans JF, Holme K.

J Clin Pharmacol. 2012 Oct;52(10):1482-93. Epub 2011 Nov 22.

PMID:
22110163
17.

Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.

Sidharta PN, Diamant Z, Dingemanse J.

Fundam Clin Pharmacol. 2014 Dec;28(6):690-9. doi: 10.1111/fcp.12079. Epub 2014 May 11.

PMID:
24734908
18.

Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects.

Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz JA, McCrary Sisk C, Radziszewski W, Wagner JA.

Platelets. 2010;21(3):191-8. doi: 10.3109/09537100903521611.

PMID:
20163197
19.

Identification of prostaglandin D2 receptor antagonists based on a tetrahydropyridoindole scaffold.

Beaulieu C, Guay D, Wang Z, Leblanc Y, Roy P, Dufresne C, Zamboni R, Berthelette C, Day S, Tsou N, Denis D, Greig G, Mathieu MC, O'Neill G.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2696-700. doi: 10.1016/j.bmcl.2008.03.015. Epub 2008 Mar 10.

PMID:
18359630
20.

Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.

Othman AA, Lenz RA, Zhang J, Li J, Awni WM, Dutta S.

J Clin Pharmacol. 2011 Apr;51(4):512-26. doi: 10.1177/0091270010370460. Epub 2010 May 21.

PMID:
20495134

Supplemental Content

Support Center